Pfizer Inc. (NYSE:PFE) Shares Sold by Jupiter Asset Management Ltd.

VaselineSeptember 14, 2024

0 4 minutes read

Jupiter Asset Management Ltd. reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 5.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,435 shares of the biopharmaceutical company’s stock after selling 6,654 shares during the period. Jupiter Asset Management Ltd.’s holdings in Pfizer were worth $3,062,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. FAS Wealth Partners Inc. raised its position in shares of Pfizer by 1.3% in the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock worth $736,000 after acquiring an additional 342 shares in the last quarter. Sachetta LLC grew its position in Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 342 shares during the period. Ironvine Capital Partners LLC boosted its stake in shares of Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 353 shares in the last quarter. Secure Asset Management LLC boosted its position in shares of Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock worth $1,632,000 after purchasing an additional 353 shares during the period. Finally, Patrick M Sweeney & Associates Inc. raised its stake in shares of Pfizer by 0.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock valued at $1,180,000 after purchasing an additional 355 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s shares.

Pfizer stock down 0.4%

Shares of NYSE:PFE opened at $29.27 on Friday. The company’s fifty day moving average is $29.21 and its two hundred day moving average is $28.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60, and a current ratio of 0.86. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.42. The stock has a market cap of $165.86 billion, a price-to-earnings ratio of -487.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68.

Want more great investment ideas?

Pfizer (NYSE:PFE – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. In the same quarter last year, the company earned $0.67 per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Stock analysts anticipate that Pfizer Inc. will record 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26. This represents a dividend of $1.68 on an annualized basis and a yield of 5.74%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts set new price targets

Several equities analysts recently commented on PFE shares. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th . Daiwa America upgraded shares of Pfizer from a “moderate-buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, September 9th. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Moderate Buy” and an average price target of $34.54, according to MarketBeat.com.

Read our latest report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. The company offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine and women’s health under the brands Eliquis, Nurtec ODT/Vydura, Zavzpret and Premarin; infectious diseases with unmet medical needs under the brand names Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; and the prevention and treatment of COVID-19 and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.